Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Ondine to pilot Steriwave at Mexico City hospital | 2 | Sharecast | ||
Mi | Mexican hospital to pilot Ondine's nasal disinfection system | 1 | Investing.com | ||
Mi | Ondine Biomedical - First Mexican Hospital Steriwave Deployment | - | RNS | ||
Mo | Ondine Biomedical - Ex-President of Mexico Champions APDT to Cut AMR | - | RNS | ||
22.07. | Ondine Biomedical gibt nach Studien-Meilenstein neue Aktien aus | 1 | Investing.com Deutsch | ||
22.07. | Ondine Biomedical - Share Issuance for ICU Study Enrollment Completion | 1 | RNS | ||
21.07. | Ondine Biomedical - UK Axes Financial support for AMR Fleming Fund | - | RNS | ||
21.07. | Ondine Biomedical - Steriwave ICU Study Completes Recruitment | - | RNS | ||
ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
14.07. | Ondine Biomedical: Steriwave-Therapie zur Infektionsprävention findet breitere Anwendung in Krankenhäusern | 1 | Investing.com Deutsch | ||
14.07. | Ondine Biomedical - Growing Use of Steriwave Across Surgery Types | - | RNS | ||
09.07. | Ondine Bourrut Lacouture to serve as Active Underwriter of Arch Syndicate 1955 | 1 | Reinsurance News | ||
08.07. | Ondine Biomedical: Kanadische Gesundheitsbehörde weitet Einsatz von Steriwave-Technologie zur Infektionsprävention aus | 2 | Investing.com Deutsch | ||
08.07. | Ondine Biomedical - Steriwave in Half of Fraser Health Hospitals | - | RNS | ||
01.07. | Ondine Biomedical - Ondine Appoints Peel Hunt as Broker | - | RNS | ||
30.06. | Ondine Biomedical - Leading Canadian Surgery Centre Adopts Steriwave | - | RNS | ||
26.06. | Ondine Biomedical - Result of AGM and voting results | 1 | RNS | ||
25.06. | Ondine Biomedical - Steriwave Standard of Care in 2nd Health Authority | - | RNS | ||
19.06. | Ondine Biomedical - Second Quebec Hospital Adopts Steriwave | - | RNS | ||
16.06. | Ondine Biomedical - UK Doctor Wins Award for NHS Steriwave Innovation | - | RNS | ||
12.06. | Ondine Biomedical - NHS Trust up for HSJ Award for Steriwave Use | - | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AVIDITY BIOSCIENCES | 46,150 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
BOLT PROJECTS | 14,320 | 0,00 % | Bolt Projects Stock Surges 38% on Strong Q2, $20M Funding; CEO: 'Demand For Vegan Silk Continues To Grow' | ||
180 LIFE SCIENCES | 10,755 | 0,00 % | 180 Life Sciences setzt auf Ethereum - Milliardenwechsel in Geschäftsstrategie | Die 180 Life Sciences Corp. (Börsenkürzel: ATNF) hat bekanntgegeben, inzwischen 82.186 Ether-Token zu halten - ein Bestand, der zum 11. August 2025 rund 349 Millionen US-Dollar wert war. Der durchschnittliche... ► Artikel lesen | |
89BIO | 9,140 | 0,00 % | 89bio, Inc. - 10-Q, Quarterly Report | ||
ARCTURUS THERAPEUTICS | 19,210 | 0,00 % | Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday | ||
SUMMIT THERAPEUTICS | 26,840 | 0,00 % | Evercore ISI hebt Kursziel für Summit Therapeutics auf 34 US-Dollar an | ||
RECURSION PHARMACEUTICALS | 5,700 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARCELLX | 70,96 | 0,00 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
ENLIVEN THERAPEUTICS | 19,985 | 0,00 % | Enliven Therapeutics, Inc Q2 Loss Climbs | ||
BEAM THERAPEUTICS | 17,520 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
ARS PHARMACEUTICALS | 15,800 | -4,93 % | ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets | ||
ADMA BIOLOGICS | 17,210 | 0,00 % | ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum | ||
ARCUTIS BIOTHERAPEUTICS | 15,625 | +6,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
VALNEVA | 4,672 | -0,17 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
QIAGEN | 42,005 | -0,26 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen |